摘要
[目的]观察重组人源化白细胞介素-2(rhIL-2)皮下注射治疗肾癌肺转移的疗效及其安全性。[方法]经病理确诊的17例肾透明细胞癌术后肺转移患者,rIL-2皮下注射治疗至少2个周期,分析总有效率(ORR),无疾病进展生存(PFS),总生存(OS)和毒副反应。[结果]17例患者中,完全缓解(CR)1例,部分缓解(PR)2例,病情稳定(SD)8例,疾病进展(PD)6例,全组有效率17.6%,疾病控制率64.7%;中位随访时间7.8个月(2～11.7个月),6个月PFS比例为60%(9/15);严重毒副反应(≥3度)少见。[结论]白细胞介素-2治疗肾癌肺转移有一定的疗效,大部分患者能够耐受毒副反应。
[Purpose] To investigate the efficacy and safety of subcutaneous injection of recombinant human interleukin-2（rhlL-2） in the treatment for renal cell carcinoma with lung metastasis. [Methods] Seventeen cases pathologically proved renal clear cell carcinoma with lung metastasis received at least 2 cycles of subcutaneous injection of rhlL-2. The overall response rate （ORR）, progression free survival （PFS）, overall survival （OS） and toxicity were analyzed. [Resuhsl The overall response rate was 17.6%, including 1 case complete response （CR）; 2, partial response （PR）; 8, stable disease （SD）, and 6, progression disease （PD）. The disease control rate was 64.7%. The median follow-up was 7.8 months （2-11.7 months）. The 6-month PFS was 60%（9/15）. Severe toxicity（≥3 grade） was rare. [Conclusions] This study confirms that subcutaneous recombinant human interleukin-2 treatment could benefit renal cell carcinoma with lung metastasis. The toxicity was tolerable.
出处
《肿瘤学杂志》
CAS
2008年第5期366-369,共4页
Journal of Chinese Oncology
关键词
白细胞介素-2
肾肿瘤
肺转移
interleukin-2
renal neoplasms
lung metastasis
